KIG
ANIP icon

Kowal Investment Group’s ANI Pharmaceuticals ANIP Stock Holding History

Kowal Investment Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1
Closed – – 157
2021
Q3 		$0 Buy
+1
New +$31 ﹤0.01% 909

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Kowal Investment Group's ANIP Position: Q4 2021 in Review

Kowal Investment Group sold out of ANI Pharmaceuticals (ANIP) in Q4 2021, closing a stake of 1 share.

Kowal Investment Group first reported a position in ANIP in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 132 funds tracked by Wall St. Rank hold ANIP as of Q4 2021.

  • Kowal Investment Group reported no remaining ANI Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Kowal Investment Group sold 1 ANI Pharmaceuticals share in Q4 2021.
  • Kowal Investment Group first reported a position in ANI Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Kowal Investment Group's ANI Pharmaceuticals position peaked at $0 in Q3 2021.
  • 132 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2021.

Based on Kowal Investment Group's 13F filing for Q4 2021, filed 11 Feb 2022.